These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Glycaemic control in type 2 diabetes. Campbell A Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416 [No Abstract] [Full Text] [Related]
8. [Combination insulin and sulfonylurea compounds in the therapy of type II diabetes mellitus]. Diem P Schweiz Med Wochenschr; 1990 Jul; 120(27-28):987-8. PubMed ID: 2197718 [No Abstract] [Full Text] [Related]
9. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted? Standl E; Schnell O Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474 [No Abstract] [Full Text] [Related]
10. Insulin in the early management of diabetic complications. Miles JM J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435 [TBL] [Abstract][Full Text] [Related]
11. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Bowker SL; Majumdar SR; Veugelers P; Johnson JA Diabetes Care; 2006 Aug; 29(8):1990-1. PubMed ID: 16873829 [No Abstract] [Full Text] [Related]
12. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Bowker et Al. Farooki A; Schneider SH Diabetes Care; 2006 Aug; 29(8):1989-90. PubMed ID: 16873827 [No Abstract] [Full Text] [Related]
13. Drugs for type 2 diabetes. Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949 [No Abstract] [Full Text] [Related]
14. [A case from practice (158). Type I diabetes in remission. Type II diabetes]. Skoda C; Spinas GA Schweiz Rundsch Med Prax; 1990 Jan; 79(1-2):25-6. PubMed ID: 2404332 [No Abstract] [Full Text] [Related]
15. Conversation with ... Ralph DeFronzo, MD: dealing with the older diabetic. Interview by Richard L. Peck. DeFronzo R Geriatrics; 1986 Dec; 41(12):89-92. PubMed ID: 3536668 [No Abstract] [Full Text] [Related]
16. Insulin initiation in Type 2 diabetes. Page S Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011 [No Abstract] [Full Text] [Related]
17. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes. Charbonnel B Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387 [No Abstract] [Full Text] [Related]
18. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. Inzucchi SE Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144 [No Abstract] [Full Text] [Related]
19. [Pharmacologic treatment of diabetes]. De Montigny P; Clerc C; Descarpentries C Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094 [No Abstract] [Full Text] [Related]
20. Follow-up of intensive glucose control in type 2 diabetes. Petrie JR N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672 [No Abstract] [Full Text] [Related] [Next] [New Search]